<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05117398</url>
  </required_header>
  <id_info>
    <org_study_id>19-01</org_study_id>
    <nct_id>NCT05117398</nct_id>
  </id_info>
  <brief_title>Dalbavancin Versus Standard Antibiotic Therapy for Catheter-related Bloodstream Infections Due to Staphylococcus Aureus</brief_title>
  <acronym>DALICATH</acronym>
  <official_title>Randomized Open-label Controlled Trial Evaluating a Single-dose Intravenous Dalbavancin Versus Standard Antibiotic Therapy During Catheter-related Bloodstream Infections Due to Staphylococcus Aureus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Annecy Genevois</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre Hospitalier de Perigueux</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ADVANZ PHARMA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>French National Network of Clinical Research in Infectious Diseases (RENARCI)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre National de Reférence des Staphylocoques</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>APHP</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Annecy Genevois</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The DALICATH study aim to demonstrate the non-inferiority of a single administration of 1500&#xD;
      mg of dalbavancin compared with standard documented antibiotic therapy for 14 days according&#xD;
      to national guidelines.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Catheter-related bloodstream infections (CR-BSIs) are the most common nosocomial bloodstream&#xD;
      infections, with an incidence as high as 8.5 to 19.8 infections per 1000 catheter-days.&#xD;
      Staphylococcus aureus is involved in about 20% of CR-BSIs and associated with significant&#xD;
      morbidity, mortality (9.3%), prolonged hospital stay (+ 9 days), and healthcare costs (35 000&#xD;
      € to 65 000 € per case). S. aureus CR-BSIs occurs mainly in frail patients with a port of&#xD;
      catheter for chemotherapy or parenteral nutrition.&#xD;
&#xD;
      According to international guidelines, management of CR-BSIs due to S. aureus includes the&#xD;
      removal and replacement of the infected catheter and a 14-day intravenous (IV) antibiotic&#xD;
      therapy. Therefore, the management of CR-BSIs due to S. aureus requires the insertion of a&#xD;
      new intravenous catheter. In turn, the new catheter can also lead to new septic complications&#xD;
      and limit the patients' autonomy. Non-adherence to these recommendations leads to&#xD;
      over-mortality and costs. To date, it is not recommended to switch to oral antibiotics in&#xD;
      such infections.&#xD;
&#xD;
      Dalbavancin is a new glycopeptide antibiotic, with an excellent bactericidal activity against&#xD;
      Gram-positive bacteria, especially S. aureus, and a prolonged half-life of 14 to 15 days. As&#xD;
      a comparison, half-life of antibiotics usually used for CR-BSIs due to S. aureus, i.e.&#xD;
      penicillin or glycopeptide, as-per sensitivity to methicillin is much lower: 1.5 to 9 hours.&#xD;
      Such prolonged half-life allows one IV injection to be sufficient and effective over 14 days&#xD;
      of treatment. This remarkable characteristic should allow patients to be promptly discharged&#xD;
      from hospital without monitoring.&#xD;
&#xD;
      The hypothesis is that in patients with CR-BSIs due to S. aureus, after catheter removal,&#xD;
      dalbavancin could be administered intravenously in a single administration after catheter&#xD;
      removal and be as effective as standard documented antibiotic therapy for 14 days according&#xD;
      to national guidelines.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 3, 2022</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">April 4, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Phase III, pragmatic, open-label, non-inferiority, randomized (1:1), multicenter trial, in patients with non-complicated CR-BSI due to S. aureus, with two parallel groups receiving 14 days of active antimicrobial therapy.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cure rate</measure>
    <time_frame>DAY 30</time_frame>
    <description>Clinical cure without relapse</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cure rate</measure>
    <time_frame>DAY 14;DAY 90</time_frame>
    <description>Clinical cure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>DAY 90</time_frame>
    <description>Death all-cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bloodstream clearance</measure>
    <time_frame>DAY 14</time_frame>
    <description>Time from first positive blood culture to first negative blood cultures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's quality of life</measure>
    <time_frame>BASELINE; DAY 14; DAY 30; DAY 90</time_frame>
    <description>Autonomy, pain and anxiety using 5-level EQ-5D scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization length of stay</measure>
    <time_frame>DAY 90</time_frame>
    <description>Hospitalization duration in days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-utility analyses</measure>
    <time_frame>DAY 90</time_frame>
    <description>Cost per avoided relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of any adverse event (AE and SAE)</measure>
    <time_frame>DAY 90</time_frame>
    <description>Proportion of patients with any adverse event</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">406</enrollment>
  <condition>Catheter Bacteremia</condition>
  <condition>Staphylococcus Aureus Infection</condition>
  <arm_group>
    <arm_group_label>Dalbavancin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dalbavancin (Xydalba®) 1500 mg - One unique dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard documented antibiotic therapy for 14 days according to national guidelines.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>As currently recommended, investigators will be encouraged to use the intravenous route for the entire duration of treatment. However, in order to interfere as little as possible with usual practice in each center, the antimicrobial therapy will be let to the choice of the physician in charge of the patient after a minimum of 7 days of intravenous treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dalbavancin</intervention_name>
    <description>A single-dose of IV dalbavancin 1500 mg</description>
    <arm_group_label>Dalbavancin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of care</intervention_name>
    <description>Standard Antibiotic therapy according national recommendations</description>
    <arm_group_label>Standard documented antibiotic therapy for 14 days according to national guidelines.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged at least 18 years;&#xD;
&#xD;
          -  Blood cultures positive for S. aureus, obtained within 72 hours before randomization&#xD;
             (the date considered is the date of the sampling, not the results);&#xD;
&#xD;
          -  CR-BSI, defined as:&#xD;
&#xD;
        One positive blood culture AND Local signs of infection at the catheter site OR at least&#xD;
        one positive blood culture obtained from the catheter and the peripheral vein, AND A&#xD;
        differential period between catheter versus peripheral blood culture positivity of at least&#xD;
        2h as recommended AND Same S. aureus isolate (same phenotype) identified from the catheter&#xD;
        and the peripheral vein blood cultures;&#xD;
&#xD;
          -  Intravascular catheter - implantable venous access device - removed before&#xD;
             randomization;&#xD;
&#xD;
          -  Informed consent form date and signed by the patient.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Polymicrobial infection&#xD;
&#xD;
          -  More than 72 hours of active antibiotic treatment targeting S. aureus (in-vitro&#xD;
             susceptibility) administered prior to randomization;&#xD;
&#xD;
          -  Patient with known valvulopathy, previous history of endocarditis, or suspicion of&#xD;
             infective endocarditis by physician in charge;&#xD;
&#xD;
          -  Suspicion of any other deep focus infections, such as arthritis, pneumonia,&#xD;
             osteomyelitis, or meningitis, presence of cerebral or peripheral emboli (arterial&#xD;
             occlusion);&#xD;
&#xD;
          -  Thrombophlebitis&#xD;
&#xD;
          -  Failure to remove any intravascular catheter which was present when first positive&#xD;
             blood culture&#xD;
&#xD;
          -  Signs of infection associated with quick SOFA score ≥ 2 at randomization&#xD;
&#xD;
          -  Patients with foreign bodies such as: prosthetic heart valve, endovascular prosthesis,&#xD;
             ventriculo-atrial shunt, pacemaker, or an automated implantable cardioverter&#xD;
             defibrillator (AICD) device&#xD;
&#xD;
          -  Severe liver disease (Child-Pugh C)&#xD;
&#xD;
          -  Severely immunocompromised patients:&#xD;
&#xD;
               -  Neutropenia (&lt; 500 neutrophils/µL) at randomization;&#xD;
&#xD;
               -  Hematopoietic stem cell transplantation within the past 6 months or planned&#xD;
                  during treatment period;&#xD;
&#xD;
               -  Solid organ transplant;&#xD;
&#xD;
          -  Contraindication to dalbavancin and/or glycopeptide&#xD;
&#xD;
          -  Life expectancy &lt; 3 months&#xD;
&#xD;
          -  Injection drug user&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  For premenopausal women: failure to use highly-effective contraceptive methods for 1&#xD;
             month after receiving study drug&#xD;
&#xD;
          -  Participation in other interventional trials within the previous three months or&#xD;
             ongoing;&#xD;
&#xD;
          -  Persons held in an institution by legal or official order;&#xD;
&#xD;
          -  Patients under guardianship or curators;&#xD;
&#xD;
          -  Patients unable to give a free and informed consent;&#xD;
&#xD;
          -  Patient not affiliated to a social security scheme: obligation of affiliation to a&#xD;
             social security scheme or to be a beneficiary.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernard CASTAN, MD</last_name>
    <role>Study Director</role>
    <affiliation>CH de Perigueux</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aurélien DINH, MD;PhD</last_name>
    <role>Study Director</role>
    <affiliation>APHP - RAYMOND POINCARE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marion NORET, MSc</last_name>
    <phone>+33 4 56 49 72 40</phone>
    <email>mnoret@ch-annecygenevois.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Caroline JEANNIN</last_name>
    <email>cjeannin@ch-annecygenevois.fr</email>
  </overall_contact_backup>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 21, 2021</study_first_submitted>
  <study_first_submitted_qc>November 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 11, 2021</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Staphylococcal Infections</mesh_term>
    <mesh_term>Bacteremia</mesh_term>
    <mesh_term>Sepsis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dalbavancin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

